Organisation of Pharmaceutical Producers of India
L to R- Mr Tapan Ray, Mr. Sam Pitroda, Shri Dilsher Singh Kalha,
Mr Ranjit Sahani, Shri Chandra Prakash Singh
Mumbai, 15
September 2012:The 46th Annual General Meeting of the Organisation of
Pharmaceutical Producers of India (OPPI) was held
today at The Taj Mahal Palace, Mumbai. The meeting was
presided over by MrRanjit Shahani, President, OPPI and Vice-Chairman &
Managing Director,
Novartis India Ltd.
On the occasion, the 46th
Annual Report was released, outlining the various
initiatives undertaken by OPPI and highlights of the major events in
2011-2012. The Report elucidates the pharmaceutical industry’s
concerns and challenges in general as well as those of
member companies by analyzing implications of various issues
related to the pharmaceutical industry.
Placing
Universal Healthcare (UHC) at the top of the agenda, OPPI's focus this year will
be on ‘Improving Access to Health’ and enabling an
environment that fosters research and innovation in the
country.
Expressing concern
over the recent policy decision on FDI and pricing, OPPI Director General Tapan Ray
said: “OPPI will continue to work in tandem
with the government and other stakeholders to uphold high standards of
governance
in all areasthat impact health and patients’
interest, including issues
related to access to medicines, investments in the
pharmaceutical sector, clinical trials, regulatory
compliances and ethical promotion of medicines, just to name a few. OPPI
member companies will continue to act responsibly and in close
collaboration with all stakeholders towards achieving the common goal of ‘health for
all’ as envisioned in Vision
2020.”
OPPI also presented Excellence Awards to
top scientists working in drug discovery and pharmacology,
apart from releasing their various publications.
Speaking on the
prospects of the pharmaceutical industry, Mr Ranjit Shahani said:
“Sustaining the growth of the
pharmaceuticalindustry in the
long term is a challenge due to various uncertainties prevailing in the
country. Further, the absence of an ecosystem that fosters innovation
will be to the long term detriment of the patient if not addressed
speedily.”
Among the key
dignitaries present on the occasion were Shri Chandra Prakash Singh,
Chairman, National Pharmaceutical Pricing Authority, Government
of
India, Shri Dilsher Singh Kalha, Secretary, Department of
Pharmaceuticals, Ministry of Chemicals &
Fertilizers, Government of India and Mr Sam
Pitroda,Advisor to the Prime Minister of
India, Public Information,
Infrastructure & Innovations as the Guest of Honour.
The AGM saw stalwarts
from the Government, Regulatory Authorities, overseas/local opinion
leaders, Heads of Companies, Senior Managers of the Pharmaceutical Industry
and other dignitaries come together and discuss key issues. More than 200
delegates participated in the OPPI
AGM.
Organisation of
Pharmaceutical Producers of India (OPPI)
established
in 1965 is a premier association of research and innovation
driven pharmaceutical companies in India and
is also a scientific and professional body. It caters to the needs of Research
based Pharmaceutical Industry thereby creating and
sustaining an environment conducive to innovation
and growth, simultaneously, facilitating industry and stakeholders
partnership through various advisory and consultative processes to achieve the
Healthcare objectives of the Nation.For more information, please visit :
www.indiaoppi.com
Comments
Post a Comment